<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>研发客 | wechat-feeds</title><link>http://MzAwNzMyNzQzNg.favicon.privacyhide.com/favicon.ico</link><description>《研发客》公众号由上海汐潮信息技术有限公司提供，行业资深中英文独立编辑记者创办。我们观察药物创新生态，报道临床研究与监管科学。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 29 Jan 2021 16:25:00 +0800</pubDate><image><url>http://MzAwNzMyNzQzNg.favicon.privacyhide.com/favicon.ico</url><title>研发客 | wechat-feeds</title><link>http://MzAwNzMyNzQzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>DJSeedin创新合作峰会：谁是下一个百济信达再鼎</title><link>https://mp.weixin.qq.com/s/EZE7fOArxcUe7BYJxWKi4w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaHWQyORNlBvuypA3Q15NS2x7MxDfS5jkvyt2cg7hNfic38jyGBb6oTgB3CEYrBZeTj9lfictnnxjxwQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>4月22-23日，上海，春季相约]]></content:encoded><pubDate>Thu, 21 Jan 2021 11:40:45 +0800</pubDate></item><item><title>在日本，患者可以参与策划新药研发｜第一现场</title><link>https://mp.weixin.qq.com/s/UIH0joq9bzRldR9qzdIbsQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGagvJibNYticHa7SYYT5juUBnouVbIfmjpQBnmwS9DQoVhDIuiao9ibKqrIe0ajI9qVoJlfs3jmiaGZxA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>日本政府和民间组织怎样宣传患者参与临床试验？]]></content:encoded><pubDate>Tue, 19 Jan 2021 23:17:10 +0800</pubDate></item><item><title>重点关注细胞和基因疗法   拜耳以创新突破引领医疗转型 | 新闻稿</title><link>https://mp.weixin.qq.com/s/qSctkzhchT2TW1HzXM0vkg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGagvJibNYticHa7SYYT5juUBeZobyZxhoX1LicWwvrgjIcIUDYpibSpFJiajAib5dtWKnmEDyibljtKenWA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>近期在外部创新方面投入巨大，已达成超过25个合作与收购项目。]]></content:encoded><pubDate>Tue, 19 Jan 2021 23:17:10 +0800</pubDate></item><item><title>丽珠：从传统迈向创新｜大话JPM</title><link>https://mp.weixin.qq.com/s/8t68wHAW-oVr_RKDjo6WfA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGagvJibNYticHa7SYYT5juUB2dQhbPEcsicgnxmSgYM4mna573xREpBWwYtnuicrAju6nxcCOuxf6sTA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>生物制品研发管线包含抗体类药物、蛋白类药物以及CAR-T细胞疗法，同时推进ADC技术平台建设。]]></content:encoded><pubDate>Tue, 19 Jan 2021 23:17:10 +0800</pubDate></item><item><title>国内首个！博雅辑因CRISPR/Cas 9基因编辑治疗β地中海贫血产品ET-01进入临床试验｜新闻稿</title><link>https://mp.weixin.qq.com/s/BgK4tSxpCIn3Eq1p1zVbKw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGb9vLfnQPLyA0v4apE8KbTUJv6Wbibmibe2iaeTHJs0eNd6v5qVRY6FZVRulewBTXooMBgKXov2tGcQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>也是国内首个获批的造血干细胞产品临床试验申请]]></content:encoded><pubDate>Mon, 18 Jan 2021 23:06:50 +0800</pubDate></item><item><title>中国CRO锐得麦携手创新药企迈入全球临床2.0时代 | 江湖</title><link>https://mp.weixin.qq.com/s/FwjUlmGOh0gG2a7O-o-Q2w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGcufHtk4ht8fK1q6RSCLrNxyAZtxhVmmkE7wWqxGF7TtVgRtQmbONAKicE0aMT09XD9FtYt6sNEEg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>年轻的CRO锐得麦，杀手锏在哪？]]></content:encoded><pubDate>Sun, 17 Jan 2021 21:55:18 +0800</pubDate></item><item><title>万春：普那布林多项联合用药数据亮眼 | 大话JPM</title><link>https://mp.weixin.qq.com/s/85wJ1hh7JPIYZdtRU4uiKQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaEM0RI3mHQb5OIN84QESzb7R0LiaAthX4H4VQqiaNUwHT68TEESv5yW29W5KvQX3mo5EuSYxfN9XoVA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>计划在今年一季度分别在中美两地提交普那布林上市申请]]></content:encoded><pubDate>Sun, 17 Jan 2021 21:55:18 +0800</pubDate></item><item><title>康希诺：新型脑膜炎疫苗接近上市 | 大话JPM</title><link>https://mp.weixin.qq.com/s/OzdDZrEKGksJOUMoUWNxPA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaEM0RI3mHQb5OIN84QESzb7UaN5X7PbUnvibfsWDvvyriaS9zEYYMf4sBoqhQlia4PZu3FMMVe1KcP2A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>管线中有16款在研疫苗]]></content:encoded><pubDate>Sun, 17 Jan 2021 21:55:18 +0800</pubDate></item><item><title>百济神州：或将公布泽布替尼治疗CLL头对头数据｜大话JPM</title><link>https://mp.weixin.qq.com/s/wpPZblLuOFVHGfiOyuLkOA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGaHd8C3icxDicuv7WDHlpM3Lj1MfD5icUQrvECb19yMuQE5J7cCF9ECZoWQPnxRRQjQRemJKsQ2VQng/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>百济神州在交易、合作、产品管线推动等一直很活跃]]></content:encoded><pubDate>Sun, 17 Jan 2021 09:10:05 +0800</pubDate></item><item><title>荣昌生物：预测泰它西普一季度获批上市｜大话JPM</title><link>https://mp.weixin.qq.com/s/hGKl6_9NfE1AI9Y2OjzAiw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGaHd8C3icxDicuv7WDHlpM3LRRg2CC74qw2fibcZibChcZJCEL14tmib9vSIcwBDjXM3THWicS9ZW1UEAw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>两大核心品种临床进展步履稳健。]]></content:encoded><pubDate>Sun, 17 Jan 2021 09:10:05 +0800</pubDate></item><item><title>中生制药：安罗替尼获批MTC第四适应症 | 大话JPM</title><link>https://mp.weixin.qq.com/s/MXI7CYA8otmtKF293gtm1g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGaHd8C3icxDicuv7WDHlpM3LRRg2CC74qw2fibcZibChcZJCEL14tmib9vSIcwBDjXM3THWicS9ZW1UEAw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>积极推动PD-1单抗AK-105，仑伐替尼、阿达木单抗和重组凝血因子Ⅷ上市]]></content:encoded><pubDate>Sun, 17 Jan 2021 09:10:05 +0800</pubDate></item><item><title>岸迈：与强生竞争EGFR/MET 双抗 | 大话JPM</title><link>https://mp.weixin.qq.com/s/KXrOqzttlshS1YSfhZ2pIA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGaHd8C3icxDicuv7WDHlpM3LRRg2CC74qw2fibcZibChcZJCEL14tmib9vSIcwBDjXM3THWicS9ZW1UEAw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>利用FIT-lg BsAb 双抗技术平台针对肿瘤细胞、免疫细胞等靶点开发双抗产品]]></content:encoded><pubDate>Sun, 17 Jan 2021 09:10:05 +0800</pubDate></item><item><title>和誉：自建一体化靶点和药物发现平台 | 大话JPM</title><link>https://mp.weixin.qq.com/s/8g_QLA4RDPyNKwe6-OydfA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ic34vsx7HDaGaHd8C3icxDicuv7WDHlpM3LRRg2CC74qw2fibcZibChcZJCEL14tmib9vSIcwBDjXM3THWicS9ZW1UEAw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>超过12条研发管线，4款产品进入临床，获得7个IND批件]]></content:encoded><pubDate>Sun, 17 Jan 2021 09:10:05 +0800</pubDate></item></channel></rss>